Polymorphisms in the CYP 2D6 Gene: Association with Plasma Concentrations of Fluoxetine and Paroxetine

Therapeutic Drug Monitoring

Volumn 25, Issue 6, 2003, Pages 738-742

  Charlier, Corinne ^a,c   Broly, Franck ^b   Lhermitte, Michel ^b   Pinto, Emmanuel ^a   Ansseau, Marc ^a   Plomteux, Guy ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CHU SART TILMAN   (Belgium)

Author keywords

Antidepressants; CYP 2D6 polymorphism; Genetic status; Plasma concentration

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450 2D6; DNA; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG METABOLISM; FEMALE; GENE DUPLICATION; GENE IDENTIFICATION; GENOTYPE; HUMAN; LEUKOCYTE; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CYTOCHROME P-450 CYP2D6; FEMALE; FLUOXETINE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS;

EID: 0345060779     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200312000-00014     Document Type: Article

References (21)

1. Steijns LS, Van Der Weide J. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem. 1998;44:914-917.
2. Sachse C, Brockmöller J, Bauer S, et al. Cytochrome P4502D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
3. Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psych Scand Suppl. 1997;391:14-21.
4. Chen S, Wen-Hwei C, Blouin RA, et al. The CYP2D6 enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther. 1996;60:522-534.
5. Steimer W, Muller B, Leucht S, et al. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chimica Acta. 2001;308:33-41.
6. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001; 104:173-192.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press, 1995.
8. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:328-389.
9. Charlier C, Pinto E, Ansseau M, et al. Relationship between clinical effects, serum drug concentration and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol Clin Exp. 2000;15:453-459.
10. Skoda R, Gonzales FJ, Demierre A, et al. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA. 1988;85:5240-5243.
11. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultra rapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90:11825-11829.
12. Broly F, Marez D, Sabbagh N, et al. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single stand conformation polymorphism analysis. Pharmacogenetics. 1995;5: 373-384.
13. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997;7:193-202.
14. Rasmussen BB, Brosen K. Is TDM a case for optimising clinical outcome and avoiding interactions of SSRIs? Ther Drug Monit. 2000;22:143-154.
15. Eap CB, Bondolfi G, Zullino D, et al. Concentrations of the enantiomers of fluoxetine and norfluxetine after multiple doses of fluoxetine in CYP2D6 poor and extensive metabolisers. J Clin Psychopharmacol. 2001;21:330-334.
16. Fjordside L, Jeppesen U, Eap CB, et al. The stereo-selective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics. 1999;9:55-60.
17. Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the SSRI paroxetine: nonlinearity and relation to the sparteine oxidation polyorphism. Clin Pharmacol Ther. 1992;51:288-295.
18. Montgomery SA, Kasper S. Side effects, dropouts from treatment and cost consequences. Int Clin Psychopharmacol. 1998;13(Suppl 2):1-5.
19. de Lean J, Barnhill J, Rogers T, et al. Pilot study of the cytochrome P4502D6 genotype in a psychiatric state hospital. Am J Psychiatry. 1998;155:1278-1280.
20. Reggiani K, Vandel P, Haffen E, et al. Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism. Encephale. 2000; 26:62-67.
21. Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001;11:573-585.